Name: DEFIANCE TRILLION DC IDX ETF (TRIL) Stock
Brand: DEFIANCE TRILLION DC IDX ETF
Rating: 3.5 (3 reviews)

Question 1

What does DEFIANCE TRILLION DC IDX ETF do?

Accepted Answer

Trillium Therapeutics, Inc. is a clinical stage immuno-oncology company, which engages in the research and development of therapies for the treatment of cancer. The company is headquartered in Mississauga, Ontario and currently employs 33 full-time employees. The company went IPO on 2005-01-11. The firm is engaged in developing therapies for the treatment of cancer. The firm is developing two clinical programs, TTI-621 and TTI-622, target CD47, a don’t eat me signal that blocks the ability of macrophages to phagocytose and destroy tumor cells. The TTI-621 is being evaluated in a multicenter, open-label phase I trial in patients with relapsed/refractory hematologic malignancies. The TTI-622 is Trillium’s second SIRPαFc fusion protein. TTI-622 consists of the same extracellular CD47-binding domain of human SIRPα as TTI-621 but has an immunoglobulin G4 (IgG4) Fc region instead of an IgG1 Fc. TTI-622 is being studied in a two-part, multicenter, open-label, phase Ia/Ib study in patients with advanced relapsed or refractory lymphoma or multiple myeloma (NCT03530683). The company focuses on developing inhibitors of CD47, a checkpoint of the innate immune system.

Question 2

Can you provide the latest stock price for DEFIANCE TRILLION DC IDX ETF?

Accepted Answer

The current stock price of TRIL is 20.0887 USD. The price decreased by -0.23% in the last trading session.

Question 3

How is the ChartMill rating for DEFIANCE TRILLION DC IDX ETF?

Accepted Answer

TRIL has a ChartMill Technical rating of 3 out of 10 and a ChartMill Fundamental rating of 0 out of 10.

Shares Outstanding	104.86M
Float	111.75M
Float Short Interest Percentage	0%
Owners (insider)	N/A
Owners (institutional)	N/A
Owners (insider) change	N/A
Owners (institutional) change	0%

DEFIANCE TRILLION DC IDX ETF (TRIL) Stock Price, Forecast & Analysis